Chaiwat Bumroongkit
Overview
Explore the profile of Chaiwat Bumroongkit including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
39
Citations
233
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ngamsutham T, Chaiwong W, Dacha S, Sitilertpisan P, Pothirat C, Duangjit P, et al.
Tuberc Respir Dis (Seoul)
. 2024 Aug;
87(4):532-542.
PMID: 39139078
Background: The sequelae of post-coronavirus disease 2019 (COVID-19) pneumonia on lung function, exercise capacity, and quality of life were observed in both shortterm and long-term. However, the study about the...
2.
Trongtrakul K, Tajarernmuang P, Limsukon A, Theerakittikul T, Niyatiwatchanchai N, Surasit K, et al.
J Clin Med
. 2024 Jan;
13(1).
PMID: 38202305
(1) Background: Early identification of severe coronavirus disease 2019 (COVID-19) pneumonia at the initial phase of hospitalization is very crucial. To address this, we validated and updated the National Early...
3.
Chaiwong W, Deesomchok A, Pothirat C, Liwsrisakun C, Duangjit P, Bumroongkit C, et al.
J Thorac Dis
. 2023 Oct;
15(9):4725-4735.
PMID: 37868845
Background: The sequelae of post-coronavirus disease 2019 (COVID-19) have been widely reported. However, the time point of the follow-up time in the previous studies varied ranging from 3-24 months and...
4.
Chaiwong W, Takheaw N, Pata S, Laopajon W, Duangjit P, Inchai J, et al.
Vaccine
. 2023 Aug;
41(40):5901-5909.
PMID: 37599143
Background: Data on humoral and cellular immune responses against SARS-CoV-2 after receiving heterologous CoronaVac/ChAdOx-1 (CoVac/ChAd) vaccination in subjects with chronic obstructive pulmonary disease (COPD) are still limited. Therefore, we determined...
5.
Deesomchok A, Liwsrisakun C, Chaiwong W, Pothirat C, Duangjit P, Bumroongkit C, et al.
Healthcare (Basel)
. 2023 Jul;
11(13).
PMID: 37444797
Many studies have demonstrated poor quality of life (QoL) at 3, 6, 12, and 24 months after coronavirus disease 2019 (COVID-19). However, these studies were limited due to cross-sectional design,...
6.
Takheaw N, Liwsrisakun C, Laopajon W, Pata S, Chaiwong W, Inchai J, et al.
Heliyon
. 2023 Apr;
9(4):e15653.
PMID: 37095993
The outbreak of the SARS-CoV-2 Omicron variant raised the need for vaccine boosting. We evaluated the efficiency of the third booster vaccine, ChAdOx-1 or BNT162b2, in causing a neutralizing antibody...
7.
Bumroongkit C, Limsukon A, Liwsrisakun C, Deesomchok A, Pothirat C, Theerakittikul T, et al.
J Atheroscler Thromb
. 2023 Mar;
30(11):1601-1611.
PMID: 36967130
Aim: To date, no studies representing the Southeast Asian population have validated the Pulmonary Embolism Severity Index (PESI) and 2019 European Society of Cardiology (ESC) risk stratification. Therefore, this study...
8.
Bumroongkit C, Tajarernmuang P, Trongtrakul K, Liwsrisakun C, Deesomchok A, Pothirat C, et al.
J Cardiovasc Dev Dis
. 2023 Feb;
10(2).
PMID: 36826556
Background: The National Early Warning Scores (NEWS) easily and objectively measures acute clinical deterioration. However, the performance of NEWS to predict mortality in patients with acute pulmonary embolism (APE) is...
9.
Liwsrisakun C, Pata S, Laopajon W, Takheaw N, Chaiwong W, Duangjit P, et al.
Asian Pac J Allergy Immunol
. 2023 Feb;
PMID: 36773278
Background: The concept of heterologous vaccination against SARS-CoV-2 infection has been adopted in Thailand with limited data on the induction of humoral and cellular immunity, particularly the CoronaVac/ChAdOx-1 (CoVac/ChAd) regimen...
10.
Chaiwong W, Takheaw N, Laopajon W, Pata S, Duangjit P, Inchai J, et al.
Vaccines (Basel)
. 2022 Dec;
10(12).
PMID: 36560586
Data on immunogenicity of adenovirus-vectored vaccine in chronic obstructive pulmonary disease (COPD) patients is limited. Therefore, we aimed to determine the humoral and cellular immune responses after homologous ChAdOx-1 vaccination...